BE-101 in hemophilia B: a genetically airtight target dropped for strategic reasons

What was tried

NCT06611436, called BeCoMe-9, was a Phase 1/2 dose-escalation and expansion study of BE-101 in adults with moderately severe or severe hemophilia B. The design was non-randomized and sequential, with BE-101 given as an intravenous infusion across ascending dose levels, and the primary endpoint was the rate of adverse events and serious adverse events through one year after dosing (ClinicalTrials.gov, NCT06611436). The sponsor was Be Biopharma. The study started on 4 December 2024, dosed an actual enrollment of 5 participants, and was terminated with a primary completion date of 29 May 2026 and a recorded reason that it was "terminated due to a strategic business decision and not due to safety concerns" (ClinicalTrials.gov, NCT06611436).

The biological hypothesis

BE-101 is an autologous engineered B-cell medicine. Patient-derived B lineage cells are expanded and edited ex vivo so that they secrete Factor IX-Padua, a hyperactive coagulation factor variant. The construct uses CRISPR-Cas9 editing at the CCR5 locus to insert an adeno-associated virus 6-encoded transgene by homology-directed repair, then the differentiated plasma cells act as durable in vivo protein factories (Liu et al., Molecular Therapy 2025, 10.1016/j.ymthe.2025.09.001). The premise was that this platform would deliver predictable, titratable, and redosable Factor IX, addressing the main gaps left by one-time gene therapy. In mice, BE-101-derived Factor IX-Padua reached steady state within two weeks and persisted beyond 184 days, with redosing producing close to dose-proportional increases and no preconditioning required (Liu et al., 2025).

The target itself is about as well validated as biology allows. The Open Targets overall association between F9 and hemophilia B is 0.888, with a genetic association component of 0.988 and a clinical component of 0.977 (Open Targets Platform). Loss-of-function in F9 causes the disease, and replacing Factor IX activity is curative in principle.

What actually happened

The trial did not fail on biology and did not fail on safety. It dosed five patients and then stopped, with the sponsor stating plainly that the decision was strategic and not driven by safety (ClinicalTrials.gov, NCT06611436). The preclinical package had been clean, including genotoxicity analysis that found no off-target issues of concern and no safety signals in tolerability and Good Laboratory Practice toxicology studies (Liu et al., 2025). There are no FAERS records for BE-101, consistent with an investigational cell therapy that never reached broad exposure (openFDA). In other words, the program was halted while its central clinical questions, durability and dose-response of secreted Factor IX in humans, were still open.

Failure mechanism, best guess

The best available reading is competitive and commercial rather than mechanistic. Hemophilia B already has approved one-time treatments. Etranacogene dezaparvovec and fidanacogene elaparvovec are approved adeno-associated virus gene therapies for the disease, and marstacimab adds a non-factor option (Current Gene Therapy 2026, 10.2174/0115665232389378250727013548). Factor IX expression after gene therapy is unusually durable, with documented expression beyond ten years in hemophilia B (Dargaud et al., Blood Reviews 2025, 10.1016/j.blre.2025.101353). A redosable B-cell platform has real conceptual advantages, but its differentiation over an already durable one-time therapy is hardest to prove exactly in the indication where the incumbents work best. The Claidex Mechanism Risk Score for F9 is 17 out of 100 (green), and the genetic-deficit term contributes only 1.7 of 15 points. The score makes the point cleanly: this is not a target failure, it is a portfolio decision against a strongly validated target in a crowded market.

How to prevent this next time

Two quantitative tools would have framed the go decision more honestly before the first patient was dosed.

First, a competitive landscape red-team expressed as a base-rate adjustment. The relevant prior is not the probability that BE-101 produces Factor IX, which is high, but the probability that a redosable platform displaces durable approved gene therapy in hemophilia B specifically. Anchoring on the incumbent durability of more than ten years (10.1016/j.blre.2025.101353), the commercial displacement prior is low, and that prior should have set the bar for advancing.

Second, a Bayesian predictive probability of success defined on the differentiation endpoint rather than the expression endpoint. The quantity that mattered was the posterior probability that BE-101 beats standard of care on a patient-relevant measure such as sustained Factor IX activity without redosing burden,

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

Evaluated against the strong incumbent prior, this probability is modest even when the engineering works, which is the situation the sponsor appears to have recognized.

The single highest leverage change would have been to launch the platform first in a hemophilia setting without a durable approved gene therapy, where the redosable and titratable advantages translate into a measurable endpoint rather than a marketing claim.

What this means for similar programs

Strong genetic validation protects against biological failure, not against strategic failure. A target can sit near the top of the evidence scale, F9 reaches an Open Targets association of 0.888 (Open Targets), and still host a terminated program because the market is already served. Novel modalities should pick their first indication where the incumbent is weakest, not where the biology is cleanest. The two are often different places.

Open questions

Did BE-101 produce measurable Factor IX-Padua in the five dosed patients, and if so at what activity level relative to the preclinical projection? Will Be Biopharma redirect the engineered B-cell platform to an indication lacking durable approved therapy? Does ex vivo manufacturing cost and complexity for an autologous B-cell product close off the redosing advantage that justifies the approach over one-time gene therapy?

Sources

1. • ClinicalTrials.gov, NCT06611436 (BeCoMe-9 design, start 4 December 2024, enrollment 5, termination reason strategic business decision and not safety, primary completion 29 May 2026). - Liu H, et al. A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B. Molecular Therapy 2025. https://(CCR5 edit, AAV6 template, FIX-Padua, steady state by 2 weeks, persistence beyond 184 days, redosable, clean genotoxicity). - Dargaud Y, et al. Long-term durability of rAAV gene therapy in hemophilia. Blood Reviews 2025. https://(Factor IX expression beyond 10 years in hemophilia B). - Anver Pasha SF, et al. The promise of gene therapy in hemophilia. Current Gene Therapy 2026. https://(approved hemophilia B options: etranacogene dezaparvovec, fidanacogene elaparvovec, marstacimab). - Open Targets Platform: F9 (ENSG00000101981) and hemophilia B (MONDO_0010604), overall association 0.888, genetic association 0.988, clinical 0.977. - openFDA FAERS: no records for BE-101. Available from: https://clinicaltrials.gov/study/NCT06611436.